Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)

• Company Description    Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $1.99 Daily Weekly Monthly 20 Day Moving Average: 509,411 shares Shares Outstanding: 15.03 (millions) Market Capitalization: $29.92 (millions) Beta: -0.07 52 Week High: $3.35 52 Week Low: $0.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.30% -29.09% 12 Week 2.05% -5.27% Year To Date -13.10% -20.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11400 WEST OLYMPIC BLVD SUITE 200 - LOS ANGELES,CA 90064 USA ph: 310-651-8041 fax: - None http://www.immixbio.com

• General Corporate Information    Officers Ilya Rachman - Chief Executive Officer and Chairman Gabriel Morris - Chief Financial Officer and Director Jason Hsu - Director Magda Marquet - Director Helen C. Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258H106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/22 Next Expected EPS Date: 06/02/23 Share - Related Items Shares Outstanding: 15.03 Most Recent Split Date: (:1) Beta: -0.07 Market Capitalization: $29.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/02/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.36 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -62.89 12/31/22 - -48.65 09/30/22 - -149.98 ROA 03/31/23 - -58.18 12/31/22 - -46.10 09/30/22 - -145.58 Current Ratio 03/31/23 - 8.85 12/31/22 - 11.70 09/30/22 - 26.92 Quick Ratio 03/31/23 - 8.85 12/31/22 - 11.70 09/30/22 - 26.92 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 0.78 12/31/22 - 0.94 09/30/22 - 1.20 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©